Globus Medical (NYSE:GMED) Shares Gap Down on Insider Selling

Globus Medical, Inc. (NYSE:GMED)’s share price gapped down prior to trading on Friday after an insider sold shares in the company. The stock had previously closed at $81.44, but opened at $74.10. Globus Medical shares last traded at $72.6550, with a volume of 1,538,117 shares.

Specifically, Director Ann Rhoads sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the sale, the director directly owned 35,384 shares of the company’s stock, valued at $3,007,640. This trade represents a 12.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GMED shares. Needham & Company LLC cut their target price on Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Royal Bank Of Canada lowered their price objective on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, October 1st. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. Finally, Wells Fargo & Company lifted their price objective on shares of Globus Medical from $99.00 to $100.00 and gave the company an “overweight” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $97.00.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and above $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, potentially supporting shareholder returns. Third-quarter results and repurchase program
• Positive Sentiment: Needham lowered its price target from $117 to $100 but maintained a Buy rating. The revised target remains above the cited share price of $81.13. Needham analyst recommendations
• Positive Sentiment: The reported acquisition of Synaptive Medical may broaden Globus’s cranial-neurosurgery technology and strengthen its position in that market. Synaptive Medical acquisition
• Neutral Sentiment: Director Ann Rhoads sold 5,000 shares for $425,000, reducing her holdings by 12.38%. One director’s sale does not by itself establish a change in the company’s outlook. Director share sale
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million consensus and fell 0.7% year over year. Full-year revenue guidance of $3.1 billion is below the $3.2 billion analyst estimate, while EPS guidance of $4.95–$5.05 is broadly in line with expectations. Quarterly results and guidance
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target from $94 to $78, citing a more cautious view of the shares. BMO analyst recommendations

Globus Medical Price Performance

The stock has a fifty day moving average of $77.44 and a 200 day moving average of $83.29. The stock has a market cap of $9.75 billion, a price-to-earnings ratio of 18.71, a P/E/G ratio of 1.40 and a beta of 0.98.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03. The business had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The business’s quarterly revenue was down .7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, equities analysts expect that Globus Medical, Inc. will post 4.99 earnings per share for the current fiscal year.

Institutional Trading of Globus Medical

Hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its position in Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares in the last quarter. Sculptor Capital LP grew its position in shares of Globus Medical by 1.9% in the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Globus Medical by 14.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock worth $133,731,000 after buying an additional 225,534 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Globus Medical by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after purchasing an additional 33,976 shares during the last quarter. Finally, Boston Trust Walden Corp lifted its stake in shares of Globus Medical by 4.4% in the third quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock worth $123,071,000 after buying an additional 69,782 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.